EPOCH 33: BIOTECH MARKET RESEARCH $JSPR

Jasper Therapeutics

Mark your calendars – a pivotal moment is on the horizon! Jasper Therapeutics is set to share P1b/2a data from briquilimab (c-Kit mAb) for Chronic Spontaneous Urticaria (CSU).  With options pricing indicating an astounding 100% volatility, the market is bracing for significant movement. Keep a close eye on this one, as it represents a major milestone in Jasper’s mission to address unmet medical needs with innovative therapies.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: P1b/2a data from Briquilimab (c-Kit mAb) for CSU

DATE: Q3 2024

IMPLIED VOLATILITY: +/- 100%

BACKGROUND: